Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Impact of prophylaxis, inhibitors, and genetics on joint outcomes according to the IPSG-MRI score in hemophilia A, B and vWD type 3
by
Seeliger, Anna
, Berg, Sebastian
, Schlagenhauf, Axel
, Uhl, Markus
, Oldenburg, Johannes
, Glonnegger, Hannah
, Zieger, Barbara
, Boeckelmann, Doris
in
arthropathy
/ Cartilage
/ Cysts
/ Disease prevention
/ hemophila A
/ hemophila B
/ Hemophilia
/ Inflammation
/ inhibitors
/ IPSG score
/ joint health
/ Original Research
/ Patients
/ Quality of life
/ Ultrasonic imaging
2026
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Impact of prophylaxis, inhibitors, and genetics on joint outcomes according to the IPSG-MRI score in hemophilia A, B and vWD type 3
by
Seeliger, Anna
, Berg, Sebastian
, Schlagenhauf, Axel
, Uhl, Markus
, Oldenburg, Johannes
, Glonnegger, Hannah
, Zieger, Barbara
, Boeckelmann, Doris
in
arthropathy
/ Cartilage
/ Cysts
/ Disease prevention
/ hemophila A
/ hemophila B
/ Hemophilia
/ Inflammation
/ inhibitors
/ IPSG score
/ joint health
/ Original Research
/ Patients
/ Quality of life
/ Ultrasonic imaging
2026
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Impact of prophylaxis, inhibitors, and genetics on joint outcomes according to the IPSG-MRI score in hemophilia A, B and vWD type 3
by
Seeliger, Anna
, Berg, Sebastian
, Schlagenhauf, Axel
, Uhl, Markus
, Oldenburg, Johannes
, Glonnegger, Hannah
, Zieger, Barbara
, Boeckelmann, Doris
in
arthropathy
/ Cartilage
/ Cysts
/ Disease prevention
/ hemophila A
/ hemophila B
/ Hemophilia
/ Inflammation
/ inhibitors
/ IPSG score
/ joint health
/ Original Research
/ Patients
/ Quality of life
/ Ultrasonic imaging
2026
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Impact of prophylaxis, inhibitors, and genetics on joint outcomes according to the IPSG-MRI score in hemophilia A, B and vWD type 3
Journal Article
Impact of prophylaxis, inhibitors, and genetics on joint outcomes according to the IPSG-MRI score in hemophilia A, B and vWD type 3
2026
Request Book From Autostore
and Choose the Collection Method
Overview
Hemophilia A (HA) and hemophilia B (HB) are X-linked-bleeding disorders caused by deficiency of clotting factors VIII and IX, while von Willebrand disease (vWD) type 3 involves the lack of von Willebrand factor and FVIII. Chronic joint damage from recurrent bleeding is a serious complication.
The aim was to investigate the association of prophylactical treatment, severity of the disease and joint outcome.
In this retrospective, single-center study we evaluated joint health in 41 patients with HA, HB, and vWD type 3 who visited our outpatient clinic since 2000 using Magnetic resonance imaging (MRI) and applied the International Prophylaxis Study Group (IPSG) score. A total of 246 MRI images (knees, elbows, ankles) were analyzed in relation to disease severity, genetics, inhibitor-formation, and therapy.
Of 41 patients, 28 (68%) had severe HA or HB, 10 (24%) moderate, one (2%) mild, and two (5%) were vWD patients. 19 patients with severe HA/HB received primary prophylaxis. Inhibitors developed in 7 patients (17%), most of them had loss-of-function mutations. We observed hemophilic arthropathy in 7/39 (18%) hemophilia patients (all with severe HA/HB). Only one of the 19 patients receiving early prophylaxis developed arthropathy, in the context of inhibitor development. Minor changes (IPSG score 1-5) were observed in 20% of joints while 74% of joints showed no alterations (IPSG score 0). Only 6% of joints showed hemophilic arthropathy (IPSG score ≥ 8) with ankle joints most frequently affected (10%). Among vWD-patients, one exhibited minor changes; the other had no detectable joint damage despite vWF-inhibitor presence.
This study shows that the IPSG score is a suitable tool for assessing joint health in patients with hemophilia and vWD. Reduced joint damage was associated with early diagnosis, consistent prophylaxis, and therapy adherence.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
MBRLCatalogueRelatedBooks
Related Items
Related Items
We currently cannot retrieve any items related to this title. Kindly check back at a later time.
This website uses cookies to ensure you get the best experience on our website.